BMS/Janssen Will Begin Phase III For Factor XIa Inhibitor Milvexian By Year-End

Phase II Showed Potential Beyond Prior Anticoagulants

 
• By Mandy Jackson
  
stethoscope twisted in heart shape lying on cardiogram chart closeup
BMS unveiled three Phase III indications: secondary stroke prevention, acute coronary syndrome and atrial fibrillation • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Cardiovascular

More from Therapy Areas